The effects of gonadotropin-releasing hormone agonist (buserelin) and orchidectomy on bone turnover markers and histomorphometry in rats

被引:6
|
作者
Mohamad, Nur-Vaizura [1 ]
Ima-Nirwana, Soelaiman [1 ]
Chin, Kok-Yong [1 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Med Ctr, Kuala Lumpur, Malaysia
来源
AGING MALE | 2020年 / 23卷 / 05期
关键词
Bone; gonadotropin-releasing hormone agonists; male osteoporosis; histomorphometry; CANCELLOUS BONE; PROSTATE-CANCER; ANDROGEN DEPRIVATION; MINERAL DENSITY; OSTEOPOROSIS; TESTOSTERONE; MEN; RESORPTION; ESTROGEN; HYPOGONADISM;
D O I
10.1080/13685538.2018.1446075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to compare the skeletal effect between GnRH agonist therapy and orchidectomy in male rats assessed using serum turnover markers and bone histomorphometry. Three-month-old male Sprague-Dawley rats (n = 46) were divided into three experimental arms, baseline, buserelin, and orchidectomy. In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline or buserelin acetate at 25 mu g/kg or 75 mu g/kg. In the orchidectomy arm, the rats were either sham-operated or orchidectomized. The rats were euthanized after the three-month treatment. Blood was collected for the evaluation of bone turnover markers. Femurs were harvested for bone histomorphometry examination. A significant increase in serum C-telopeptide of type 1 collagen was observed in the orchidectomized group compared with the sham group (p < .05). Structural histomorphometry analysis showed that both buserelin (25 mu g/kg and 75 mu g/kg) and orchidectomy significantly decreased the trabecular bone volume, number and significantly increased trabecular separation in rats compared with their respective controls (p < .05). Osteoclast number and eroded surface were significantly increased in both buserelin (25 mu g/kg and 75 mu g/kg) and orchidectomized group compared with their respective controls (p < .05). As a conclusion, buserelin causes deterioration of bone microarchitecture and increased bone resorption similar to orchidectomy after three months.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 50 条
  • [21] Serotonin transporter binding is increased by a gonadotropin-releasing hormone agonist in female rats
    Overgaard, A.
    Lie, M. E. K.
    Jorgensen, C. V.
    Mikkelsen, J. D.
    Knudsen, G. M.
    Frokjaer, V. G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S193 - S194
  • [22] SHORT-TERM UTILIZATION OF A GONADOTROPIN-RELEASING HORMONE AGONIST (BUSERELIN) FOR INDUCTION OF OVULATION IN AN INVITRO FERTILIZATION PROGRAM
    LOUMAYE, E
    DECOOMAN, S
    ANOMA, M
    PSALTI, I
    DEPREESTER, S
    SCHMIT, M
    THOMAS, K
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 541 : 96 - 102
  • [23] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)
  • [24] INTRANASAL GONADOTROPIN-RELEASING HORMONE AGONIST AS A CONTRACEPTIVE AGENT
    BERGQUIST, C
    NILLIUS, SJ
    WIDE, L
    LANCET, 1979, 2 (8136): : 215 - 217
  • [25] GONADOTROPIN-RELEASING HORMONE AGONIST TREATMENT OF ENDOMETRIOSIS AND MYOMAS
    GIUDICE, LC
    WESTERN JOURNAL OF MEDICINE, 1990, 152 (04): : 409 - 409
  • [26] Depression in women treated with a gonadotropin-releasing hormone agonist
    Toren, P
    Dor, J
    Mester, R
    Mozes, T
    Blumensohn, R
    Rehavi, M
    Weizman, A
    BIOLOGICAL PSYCHIATRY, 1996, 39 (05) : 378 - 382
  • [27] Utilization of gonadotropin-releasing hormone agonist products in adolescents
    Woods, Corinne
    Ho, Amy
    Dutcher, Sarah K.
    Ajao, Adebola
    Hawrusik, Rebecca
    Schoeplein, Ryan
    Moeny, David
    Huang, Ting-Ying
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 319 - 320
  • [28] Luteal phase support with gonadotropin-releasing hormone agonist
    Tsui, Kuan-Hao
    Lin, Li-Te
    Wang, Peng-Hui
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (10) : 505 - 507
  • [29] HYPOTHALAMIC REGULATION OF PITUITARY GONADOTROPIN-RELEASING HORMONE RECEPTORS - EFFECTS OF GONADOTROPIN-RELEASING HORMONE IMMUNONEUTRALIZATION
    CLAYTON, RN
    POPKIN, RM
    FRASER, HM
    ENDOCRINOLOGY, 1982, 110 (04) : 1116 - 1123
  • [30] Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism
    Palomba, S
    Orio, F
    Morelli, M
    Russo, T
    Pellicano, M
    Nappi, C
    Mastrantonio, P
    Lombardi, G
    Colao, A
    Zullo, F
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10): : 4476 - 4481